


Estimated New Cancer Deaths
By Gender for all Sites and
for Gastrointestinal Organs
2019/USA

	Estimated New Cases			Estimated New Deaths		
	Total	Male	Female	Total	Male	Female
All Sites	1,762,450	870,970	891,480	606,880	321,670	285,210
Digestive System	328,030	186,080	141,950	165,460	97,110	68,350
Esophagus	17,650	13,750	3,900	16,080	13,020	3,060
Stomach	27,510	17,230	10,280	11,140	6,800	4,340
Small Intestine	10,590	5,610	4,980	1,590	890	700
Colon*	101,420	51,690	49,730	51,020	27,640	23,380
Rectum	44,180	26,810	17,370			
Anus, Anal Canal & Anorectum	8300	2,770	5,530	1,280	520	760
Liver & Intrahepatic Bile Duct	42,030	29,480	12,550	31,780	21,600	10,180
Gallbladder & other biliary	12,360	5,810	6,550	3,960	1,610	2,350
Pancreas	56,770	29,940	26,830	45,750	23,800	21,950
Other Digestive Organs	7,220	2,990	4,230	2,860	1,230	1,630

*Deaths for colon & rectum cancers are combined because of a large number of deaths from rectal cancer misclassified as colon.
American Cancer Society Statistics

FARGO



I enclose my donation of _____ dollars for FARGO. (Pls. make cheque payable to FARGO)

Name: _____

Address: _____

Phone #: _____

Fax #: _____

E-mail: _____

Signature: _____

Dr. Paul H. Sugarbaker
Foundation for Applied Research
in Gastrointestinal Oncology
3629 Fulton St. NW
Washington, DC 20007

* IRS Section 501(c)(3) exempt private foundation

*FARGO Tax Identification No. 52-1797893

**Foundation for Applied
Research in
Gastrointestinal Oncology**

Dr. Paul H. Sugarbaker
Foundation for Applied Research
in Gastrointestinal Oncology
3629 Fulton St. NW
Washington, DC 20007

The FARGO Mission

1. To maintain and enhance a multidisciplinary approach to the treatment of gastrointestinal cancer. This includes the prevention and treatment of carcinomatosis and sarcomatosis. The proper combinations of surgery, intraperitoneal chemotherapy, intravenous chemotherapy, radiation therapy, and hyperthermia are a priority for these efforts. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) are being optimized!
2. To provide monetary support for an international program in gastrointestinal oncology. FARGO is a major supporter of the educational initiatives of the Peritoneal Surface Oncology Group International (PSOGI).
3. To provide the general public with information about the needs of patients with gastrointestinal cancer. Treatment failure with primary disease can be prevented. Metastases can be cured. Select the proper treatment to get good results.
4. To provide the general public with information about the needs for clinical and basic science research in gastrointestinal cancer. To emphasize the pressing need for cytoreductive surgical expertise in the management of peritoneal metastases.
5. To provide international meetings for clinicians and researchers wishing to prevent and improve the treatment of gastrointestinal cancer. The outreach is global.

Foundation for Applied Research in Gastrointestinal Oncology

Paul H. Sugarbaker, M.D.
Foundation for Applied Research
in Gastrointestinal Oncology

3629 Fulton St. NW
Washington, DC 20007

Tel #: 202-844-6061

Fax #: 202-844-2552

E-mail: Paul.Sugarbaker@outlook.com

The Foundation for Applied Research in Gastrointestinal Oncology (FARGO) is a unique organization with a well-defined mission. We are pledged to promote clinical and laboratory research in gastrointestinal cancer, especially the cure of peritoneal metastases. Research in the peritoneal spread of gastrointestinal cancer has been neglected in the past because of the lack of progress in this field. Recent breakthroughs suggest that rapid advancement can be achieved with innovative research efforts. CRS works! HIPEC works!

FARGO is a not-for-profit organization with clinical research facilities located at 3629 Fulton St. NW, Washington, DC. As a not-for-profit organization we rely on the generosity of corporate, foundation and individual donors to further our research.

For information about gastrointestinal cancer, FARGO and how you can support this vital research, please call (202) 844-6061.